Navigation Links
Longer Antiviral Therapy Reduces Lung Transplant Complications
Date:6/14/2010

Study finds 12-month course of valganciclover wards off dangerous CMV infections

MONDAY, June 14 (HealthDay News) -- Extended antiviral treatment after a lung transplant may help prevent dangerous complications and organ rejection, a new study from Duke University Medical Center shows.

A common cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes mild effects but can be life-threatening for transplant patients. Standard preventive therapy involves taking the drug valganciclovir (Valcyte) for up to three months. But even with this treatment, most lung transplant patients develop CMV infections within a year.

The Duke study included 136 patients who completed three months of oral valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of oral valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 different centers (one group of which received the additional medication and a control group that received the placebo, with neither the researchers nor the participants knowing who was in the control group).

Researchers found that CMV infection occurred in 10 percent of the extended treatment group, compared to 64 percent of the placebo group. Pneumonia caused by CMV virus occurred in 4 percent of the extended-treatment group and in 32 percent of the placebo group.

"We found that 12 months of oral valganciclovir was extremely effective and led to a dramatic reduction in the rate of CMV infection and disease," Dr. Scott Palmer, scientific director of the Lung Transplant Program at Duke University Medical Center, said in a university news release.

Potential side effects of valganciclovir include nausea, diarrhea, anemia and other blood disorders, retinal detachment, headache, fever, vomiting, mental changes and other problems. However, the study "showed that there was no increased or added toxicity with the extended course of treatment," Palmer said.

"In addition, the study examined viral resistance mutations and demonstrated that extended therapy did not lead to increased drug resistance, a potential concern with longer courses of treatment," Palmer added.

The study, published in the June 15 issue of the Annals of Internal Medicine, was funded by Roche Pharmaceuticals, which makes Valcyte.

More information

The American Academy of Family Physicians has more about CMV.



-- Robert Preidt



SOURCE: Duke Medicine, June 14, 2010. news release.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Using Nicotine Patch Longer Boosts Efforts to Quit
2. Sedation Linked to Longer Stay in ICU
3. Zambian study finds longer breastfeeding best for HIV-infected mothers
4. Pet Health Insurance Grows as Pets Live Longer and Healthier Lives
5. Marijuana Use No Longer Dropping Among U.S. Teens
6. Looking Younger Than Your Age May Mean Longer Life
7. Military children face more emotional challenges as parental deployments grow longer, study finds
8. Glaucoma Drugs May Play Role in Longer Life
9. Biological clock could be a key to better health, longer life
10. Big Smiles, Longer Lives?
11. Perhaps a longer lifespan, certainly a longer health span
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Longer Antiviral Therapy Reduces Lung Transplant Complications
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Usually, ... from the daily wardrobe. However, for those self-conscious about a double chin, this means ... have the ideal solution. , “For most people, a double chin is undesirable,” ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... has relocated its corporate headquarters to a new, more expansive office space in ... October 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. located at ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... work, the Self-Funding Success website has recently developed and published an informational resource ... ” was created based on common inquiries the site’s team of third party ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With expansion and ... Georgia, in early March. , The seed processing plant opened in Marshallville in 2006, ... 2016. The new office allows opportunity for transition of Patten Seed operations to the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... -- Summary This report provides all ... its partnering interests and activities since 2010. Description The ... insight into the partnering activity of one of the world,s ... are prepared upon purchase to ensure inclusion of the most ... report will be delivered in PDF format within 1 working ...
(Date:3/27/2017)... -- A recent study at Shriners Hospitals for Children – ... country dedicated to the treatment of pediatric burns and ... Surfacide Helios ® UV-C Disinfection System is ... not killed by the EVS (manual) cleaning process alone." ... Association,s 49th Annual Meeting in Boston ...
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, ... intends to offer shares of common stock in an ... on file with the Securities and Exchange Commission (the ... conditions, and there can be no assurance as to ... as to the actual size or terms of the ...
Breaking Medicine Technology: